Becton, Dickinson & Company (NYSE:BDX) announces its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System has been CE marked to the IVD Directive (98/79/EC).
The new test delivers results in 15 minutes on an easy-to-use, portable instrument. This new assay is expected to be commercial available at the end of October in Europe.
https://seekingalpha.com/news/3618274-becton-dickinsons-sars-covminus-2-antigen-test-okd-in-europe
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.